NCR3 and leukemia: Due to the low expression of the NKp30 ligands B7H6 and BAG6 on leukemia target cell lines, we hesitate to ascribe this activity as being a key point of differentiation between the killing activities we described, but it indicates that transduction with a CAR may give rise to a different innate immune effector activity than that seen in UTD.